Please login to the form below

Not currently logged in
Email:
Password:

Helsinn Therapeutics names Paul Rittman as CEO

He replaces William Mann, who stepped down on 28 February

Helsinn, a Swiss pharmaceutical group focused on cancer care products, has appointed Paul Rittman as its new chief executive officer.

Rittman, who succeeds William Mann, takes up his new role on 5 March and has pharmaceutical industry experience from previous commercial and general management roles.

Riccardo Bragila, vice chairman and chief executive officer for Helsinn Group, said: “I am delighted to welcome aboard Paul Rittman, who has over 30 years’ experience in pharmaceutical sales and marketing with oncology and across a range of disease areas in North America.

“I am sure his expertise, experience and network will prove invaluable in this key commercial moment for the Helsinn Group.”

Rittman most recently served as senior vice president and general manager, US oncology, leading Teva Pharmaceuticals’ oncology activities for its branded products operations.

Prior to his time at Teva, he also held a number of other senior commercial roles at Intrabiotics and Aventis.

Rittman said: “I have always been impressed with Helsinn’s core values of quality, integrity and respect and so I am delighted to be joining at this time.

“Helsinn is an international pharmaceutical business strongly committed to growth through investing in oncology while working to improve the everyday lives of people with cancer.”

1st March 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....